利瑞魯單抗
| 單克隆抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | KIR2DL1/2/3 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1000676-41-4 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6452H9918N1698O2030S46 |
| 摩爾質量 | 145,228.93 g·mol−1 |
利瑞魯單抗（INN：lirilumab）是一種人單克隆抗體，設計用於治療癌症。[1]它與KIR2DL1/2/3結合來發揮作用。[2]
該藥物由Innate Pharma開發，並授權給百時美施貴寶。
臨床試驗
[編輯]一項針對急性骨髓性白血病的II期臨床試驗[3]於2017年提前終止（「失敗」）。[4]
該藥物已註冊用於頭頸鱗狀細胞癌（SCCHN）的試驗，[5]但可能會被放棄。[6]
截至2017年11月[update]，九項利瑞魯單抗臨床試驗已註冊為活躍狀態。[7]
參考資料
[編輯]- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Lirilumab （頁面存檔備份，存於網際網路檔案館）, American Medical Association.
- ^ Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. September 2009, 114 (13): 2667–77. PMC 2756126
. PMID 19553639. doi:10.1182/blood-2009-02-206532.
- ^ Clinical trial number NCT01687387 for "Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)" at ClinicalTrials.gov
- ^ Innate Pharma Leukemia Candidate Lirilumab Fails Phase II Trial. Feb 2017. [2024-05-26]. （原始內容存檔於2017-12-01）.
- ^ Clinical trial number NCT03341936 for "Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck " at ClinicalTrials.gov
- ^ Bad news for Innate Pharma as BMS-backed drug stumbles nov 2017. [2024-05-26]. （原始內容存檔於2023-12-29）.
- ^ lirilumab trials. [2024-05-26]. （原始內容存檔於2018-11-05）.
